Head-to-Head battle: new drug challenges standard treatment for fatal lung disease
Disease control
Not yet recruiting
This study aims to see if a new drug called LYT-100 (deupirfenidone) works better and is as safe as the current standard drug, pirfenidone, for adults with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 1,100 participants will be randomly assigned to …
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated Apr 02, 2026 09:12 UTC